Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Here’s Why

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) gapped down prior to trading on Tuesday . The stock had previously closed at $27.05, but opened at $25.7101. Chugai Pharmaceutical shares last traded at $26.64, with a volume of 21,476 shares.

Chugai Pharmaceutical Trading Down 0.7%

The firm has a 50-day simple moving average of $23.70 and a two-hundred day simple moving average of $24.03. The company has a market capitalization of $88.36 billion, a price-to-earnings ratio of 33.56 and a beta of 0.64.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings results on Friday, October 24th. The company reported $0.23 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 20.63% and a net margin of 32.74%.The business had revenue of $2.26 billion during the quarter. On average, sell-side analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.